GRHL2 Upregulation Predicts a Poor Prognosis and Promotes the Resistance of Serous Ovarian Cancer to Cisplatin.

Nie, Yanting; Ding, Yiling; Yang, Mengyuan

Nie, Yanting; Ding, Yiling; Yang, Mengyuan.

Afiliação

Nie Y; Department of Obstetrics and Gynecology, Second Xiangya Hospital of Central South University, Changsha, People's Republic of China.
Ding Y; Department of Obstetrics and Gynecology, Second Xiangya Hospital of Central South University, Changsha, People's Republic of China.
Yang M; Department of Obstetrics and Gynecology, Second Xiangya Hospital of Central South University, Changsha, People's Republic of China.

Onco Targets Ther ; 13: 6303-6314, 2020.

Article em En | MEDLINE | ID: mdl-32636649

Palavras-chave

ERK/MAPK; GRHL2; SOC; cisplatin resistance; serous ovarian cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Onco Targets Ther Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google